incrementalnew treatment
Omalizumab reported effective for urticarial symptoms in select HUVS patients
Hypocomplementemic Urticarial Vasculitis Syndrome →Summary
Several case reports described partial to complete control of urticarial wheals with omalizumab (anti-IgE) in HUVS patients, though systemic manifestations were less responsive. This suggests IgE-dependent mast cell activation may contribute to the urticarial component independently of complement-mediated vascular injury.
Related treatments
More from Hypocomplementemic Urticarial Vasculitis Syndrome
incrementalTreatment update
JAK inhibition shows partial response in DNASE1L3-deficient HUVS
incrementalTreatment update
Pediatric HUVS: rituximab most effective in long-term follow-up
incrementalNew research
Novel DNASE1L3 variant in Emirati families demonstrates secretion defect mechanism
incrementalepidemiology
Systematic review estimates HUVS prevalence at fewer than 1 per million
ID: hypocomplementemic-urticarial-vasculitis-syndrome-update-8Type: new_treatmentImpact: incremental